Prostate Cancer: Endorectal MR Imaging and MR Spectroscopic Imaging—Distinction of True-Positive Results from Chance-detected Lesions 1

Department of Radiology, University of California, Box 0628, M-372, San Francisco, CA 94143-0628, USA.
Radiology (Impact Factor: 6.87). 02/2006; 238(1):192-9. DOI: 10.1148/radiol.2381041675
Source: PubMed


To retrospectively investigate size criteria for the identification of chance-detected lesions at endorectal magnetic resonance (MR) imaging and MR spectroscopic imaging of prostate cancer.
Approval of the committee on human research and written informed consent were obtained. This study was HIPAA compliant. Endorectal MR imaging and MR spectroscopic imaging were performed with a 1.5-T MR imager in 48 men with a mean age of 59 years (age range, 47-75 years) prior to radical prostatectomy. Two independent readers recorded the size and location of all suspected peripheral zone tumor nodules on MR images alone and on images obtained with combined MR imaging and MR spectroscopic imaging. Nodules detected at MR imaging were classified as matched lesions if tumor was present in the same location at step-section histopathologic review. For all matched lesions, kappa values were calculated to examine agreement between measured and actual tumor size. Lesions that were overmeasured at MR imaging with a kappa value of less than 0.2 were considered chance-detected lesions.
At MR imaging, two of 27 and four of 35 matched lesions for readers 1 and 2, respectively, were chance-detected lesions. The corresponding numbers of lesions at combined MR imaging and MR spectroscopic imaging were one of 21 and one of 31, respectively. In all but two cases, the measured diameter of chance-detected lesions was more than twice that of the diameter at histopathologic analysis. By using this diameter threshold to distinguish true-positive results, the mean diameter of detected tumors at histopathologic analysis was 15 mm compared with 4 mm for both undetected and chance-detected tumors (P < .05).
To ensure uniformity in the comparison of scientific studies, peripheral zone tumors detected at MR imaging and MR spectroscopic imaging of the prostate that are in the same location as tumors detected at histopathologic review should be considered chance-detected lesions if the MR transverse diameter is more than twice the histopathologic transverse diameter.

Full-text preview

Available from:
  • Source
    • "It could be concluded that the addition of MRS to MRI increases the overall accuracy of prostate cancer tumor volume measurement, although measurement variability limits consistent quantitative tumor volume estimation, particularly for small tumors. In a study by Hom et al. [42], overestimation of tumor volume was observed once again when a truepositive lesion is defined with MRI and MRS by size alone. Given the reported limitation of MRI and MRS to assess tumor volume, the authors concluded that the assumption that a technically successful dose escalation in spectroscopically suspicious locations implies improved clinical outcome must be viewed with caution [43]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Prostatic neoplasms are not uniformly distributed within the prostate volume. With recent developments in three-dimensional intensity-modulated and image-guided radiation therapy, it is possible to treat different volumes within the prostate to different thresholds of doses. This approach has the potential to adapt the dose to the biologic aggressiveness of various clusters of tumor cells within the gland. The definition of tumor burden volume in prostate cancer can be facilitated by the use of magnetic resonance spectroscopy (MRS). The increasing sensitivity and specificity of MRS to the prostate is causing new interest in its potential role in the definition of target subvolumes at higher risk of failure following radical radiotherapy. Prostate MRS might also play a role as a noninvasive predictive factor for tumor response and treatment outcome. We review the use of MRS in radiation therapy for prostate cancer by evaluating its accuracy in the classification of aggressive cancer regions and target definition; its current role in the radiotherapy planning process, with special interest in technical issues behind the successful inclusion of MRS in clinical use; and available early experiences as a prognostic tool.
    Full-text · Article · Jul 2007 · Neoplasia (New York, N.Y.)
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Human and animal studies have shown that propionyl-L-carnitine, increasing carnitine content, improves the energy metabolism of ischemic skeletal muscle. The aim of the study was to evaluate the accuracy of Doppler continuous wave, Treadmill test and 31Phosphorus magnetic resonance spectroscopy in determining the efficacy of propionyl-L-carnitine in patients with peripheral arterial disease. Experimental design: Prospective study. University hospital. Eighteen male patients with peripheral arterial disease (category 3) and 8 healthy volunteers form the basis of the study. Patients quit smoking, start physical training (2-3 Km walk per day) and were assigned to medical therapy consisting of propionyl-L-carnitine (8 patients) or placebo (10 patients). Patients were studied with Doppler continuous wave, Treadmill test and 31Phosphorus magnetic resonance spectroscopy at day 0 and at day 90. The following parameters were assessed by the principal component analysis: clinical (absolute claudication, ankle brachial index at rest and at 2, 5 and 10 minutes after completing Treadmill exercises) and biochemical (inorganic phosphorus/phosphocreatine ratio and pH profiles at 20% and 50% of the maximum load, the recovery half time of phosphocreatine, number of exercise steps and slope of linear relationship between muscle power and inorganic phosphorus/phosphocreatine ratio). Final evaluation showed a significant improvement of clinical and biochemical variables (p < 0.05 and p < 0.02 respectively). Breaking down the results on the basis of the two study arms, 31Phosphorus magnetic resonance spectroscopy showed a significant improvement of biochemical variables in the group of patients treated with propionyl-L-carnitine (p < 0.05) and was more sensitive in the evaluation of changes induced by 90-day treatment as compared with the other noninvasive examinations. 31P-MRS permits the evaluation of muscle metabolic effect induced by PLC after a 90-day-period in patients affected by category 3 of peripheral arterial disease and it is a more sensitive tool in the evaluation of the pharmacological effects of medical therapy.
    Full-text · Article · Dec 1999 · Panminerva medica

  • No preview · Article · Sep 2006
Show more